SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gets USFDA nod for generic antibiotic

05 Dec 2011 Evaluate

Lupin Ltd has received final approval from the US health regulator for its generic antibiotic minocycline hydrochloride extended-release tablets used for treating acne. The approval by the US Food and Drug Administration (USFDA) has been granted to the company’s subsidiary, Lupin Pharmaceuticals Inc, for tablets of 65 mg, 80 mg, 105 mg and 115 mg strengths. The tablets are generic versions of Medicis Pharmaceutical Corporation’s patented drug Solodyn.

It is an oral antibiotic approved to treat only the red, pus-filled pimples of moderate to severe acne in patients 12 years of age and older. Citing market research firm IMS’ September 2011 data, the company said Solodyn had sales of $750 million.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×